Skoči na glavni sadržaj

Izlaganje sa skupa

METABOLIC ALTERATIONS ASSOCIATED WITH FIRST AND SECOND GENERATION ANTIPSYCHOTICS: AN TWENTY-YEARS OPEN STUDY

Franza Francesco ; Neuropsychiatric Center Villa dei Pini Avellino, Italy
Alba Cervone ; Mental Health Deptartmet of Foggia. Foggia, Italy


Puni tekst: engleski pdf 546 Kb

str. 184-187

preuzimanja: 142

citiraj


Sažetak

Introdution: The initial enthusiasm for atypical antipsychotics, with a lower incidence of extra pyramidal symptoms, was
tempered by the association with metabolic disorders. The presence of metabolic alterations significantly influences morbidity and
patients’ quality life. We performed this open-study to determine the relationship between antipsychotic efficacy and side effects,
especially the impact of various antipsychotics on metabolic parameters after 20-year treatment with atypical (SGA) and typical
antipsychotics (FGA).
Method: 62 psychiatric schizophrenic inpatients treated with typical (haloperidol) and atypical (clozapine, risperidone,
olanzapine, quetiapine, aripiprazole) antipsychotics were studied over 20 years. Some biological parameters such as blood arterial
pressure, lipidic and glucidic profile, liver enzymes, complete blood count, electrocardiogram and body weight (and body mass
index) were collected.
Results: The results have demonstrated a not homogeneous statistically significant variation of the lipidic and glicidic profile but
we have also found a reduction of the recorded values at endpoint vs baseline in aripiprazole and haloperidol groups vs clozapine,
olanzapine, and quetiapine groups.
Conclusions: We want to point out that to endpoint of the period of observation (20 years) the patients with typical antipsychotics
haloperidol reported satisfactory and a better glycemic and lipidic profiles than previous pharmacological treatments with
antipsychotics of second generation. Optimal monitoring should include assessments of fasting glucose, lipids, cholesterol, and blood
pressure.

Ključne riječi

metabolic syndrome; first generation antipsychotics; second generation antipsychotics

Hrčak ID:

265716

URI

https://hrcak.srce.hr/265716

Datum izdavanja:

5.11.2014.

Posjeta: 449 *